Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.40-12.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HUMA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain Nasdaq listing by meeting minimum bid price | Management is addressing Nasdaq listing compliance to maintain its listing. | Broken | Fails to maintain minimum bid price required by Nasdaq | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, early-commercialization healthcare business, not a proven durable compounder. The long-term thesis is in a watch state: management is making progress on commercialization and filings, while recent performance, execution volatility, and elevated risk remain concerns.
HUMA is valued at a premium to peers, with the valuation model pointing to optionality, or value tied to possible future opportunities; confidence in that model is low. The evidence flags expensive valuation, but not the full combination of expensive valuation, weak fundamentals, and turbulent conditions, so it suggests limited overall fragility from what is priced in.
Near term, Symvess sales have increased from $0.1 million in 2025-Q2 to $0.4 million in 2026-Q2, and management plans an ATEV filing for dialysis access in the second half of 2026. These are signs of progress, but the company remains loss-making, had a recent earnings miss, and faces unresolved Nasdaq listing compliance notices. The next print carries elevated miss risk, while recent performance remains below its industry cohort.
Over the multi-year view, the thesis hinges on whether Symvess commercialization and ATEV regulatory progress translate into stronger financial performance. In the near term, weakening jobs data could weigh on cyclical healthcare names, while continued strong results from sector bellwethers could support sector momentum; misses or lower guidance from those companies could weaken that tailwind. Resolution of the listing compliance issue and steadier management execution are also important swing factors.
For the next 1 to 3 years, HUMA has visible commercial and regulatory progress, but its loss-making profile, elevated risks, and unresolved listing issue leave the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company raised $50 million in a public offering to improve financial stability. |
| Improving |
| Fails to secure capital or liquidity runs critically low |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “Humacyte intends to use the net proceeds from the offering to fund the commercialization of Symvess, the planned filing of a Biologics License Application supplement in a dialysis indication, and related activities, the development of the product candidates in its pipeline, and for working capital and general corporate purposes.” “The increase in other net expense for the three months ended June 30, 2026 and the decrease in other net income for the six months ended June 30, 2026 compared to the prior year periods resulted primarily from the non-cash remeasurement of the contingent earnout liability and other derivative liabilities.” Delivery assessment Nov 5, 2026 |
Expand strategic partnerships to boost market reach | Humacyte expands strategic partnerships, like the VA hospital contract. | Improving | Revenue growth falls below $6 million in FY26 | Revenue: $406,000 FY2026-Q2; GAAP. Published target: Revenue grows to >=$26 million in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026406,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.25 → $-0.28 · observed estimates
$0.03B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-07-25 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-07-26 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-07-27 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-07-28 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-07-29 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-07-30 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-07-31 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-01 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-08-02 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-03 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-08-04 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-05 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-08-06 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-07 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-08-08 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-09 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-10 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-12 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-13 | $-0.24 | $26,305,400 | 3 / 5 |
| 2026-08-14 | $-0.25 | $26,300,800 | 3 / 4 |
| 2026-08-15 | $-0.25 | $26,300,800 | 4 / 4 |
| 2026-08-16 | $-0.25 | $26,300,800 | 4 / 4 |
| 2026-08-17 | $-0.25 | $26,300,800 | 4 / 4 |
| 2026-08-18 | $-0.25 | $26,300,800 | 4 / 4 |
| 2026-08-19 | $-0.25 | $26,300,800 | 4 / 4 |
| 2026-08-20 | $-0.24 | $21,738,800 | 4 / 4 |
| 2026-08-21 | $-0.24 | $21,738,800 | 4 / 4 |
| 2026-08-22 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-23 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-24 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-25 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-26 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-27 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-28 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-29 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-30 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-08-31 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-01 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-02 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-03 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-04 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-05 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-06 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-07 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-08 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-09 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-10 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-11 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-12 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-13 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-14 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-15 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-16 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-17 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-18 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-19 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-20 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-21 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-22 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-23 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-24 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-25 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-26 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-27 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-28 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-29 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-09-30 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-01 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-02 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-03 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-04 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-05 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-06 | $-0.24 | $21,730,060 | 4 / 4 |
| 2026-10-07 | $-0.28 | $21,730,060 | 4 / 4 |
| 2026-10-08 | $-0.28 | $21,730,060 | 4 / 4 |
| 2026-10-09 | $-0.28 | $21,730,060 | 4 / 4 |
| 2026-10-10 | $-0.28 | $21,730,060 | 4 / 4 |
| 2026-10-11 | $-0.28 | $21,730,060 | 4 / 4 |
| 2026-10-12 | $-0.28 | $21,730,060 | 4 / 4 |
| 2026-10-13 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-14 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-15 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-16 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-17 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-18 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-19 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-20 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-21 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-22 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-23 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-24 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-25 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-26 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-27 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-28 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-29 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-30 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-10-31 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-11-01 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-11-02 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-11-03 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-11-04 | $-0.28 | $21,738,800 | 4 / 4 |
| 2026-11-05 | $-0.28 | $21,738,800 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.